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Mass spectral and chromatographic analysis demonstrates the presence of 14,15-, 11,12- and 8,9-epoxyeicosatrienoic acids (44q6, 33% and 23% of 
the total, respectively) in human kidney cortex. Chiral analysis of the human renal expoxyeicosatrienoic a ids shows the formation of 8,9-, 11,12- 
and 14,15-epoxyeicosatrienoic acids in a l:l, 41 and 2: 1 ratio of antipodes, respectively. These results demonstrate the biosynthetic origin of the 
human kidney 11,12- and 14,15-epoxyeicosatrienoic acids and suggest a role for renal cytochrome P-450 in the bioactivation of endogenous pools 
of arachidonic acid. 
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1. INTRODUCTION 
The metabolism of arachidonic acid by cyclooxy- 
genase or lipoxygenases generates everal eicosanoids 
which play significant roles in renal function [1,2]. 
More recently, in vitro studies have shown that 
subcellular fractions or isolated cell preparations ob- 
tained from rat, rabbit or human kidneys actively 
metabolize arachidonic acid via a cytochrome P-450 
dependent epoxygenase activity to 5,6-, 8,9-, 11,12- and 
14,l Sepoxyeicosatrienoic acids [2-41. The potential 
significance of this reaction has been highlighted by: (i) 
the documentation of the EETs as endogenous consti- 
tuents of human urine and of rat and rabbit kidney 
[5-71, and (ii) by their potent in vitro biological ac- 
tivities as inhibitors of ion transport in isolated cortical 
collecting tubules [8] and of vasopressin stimulated 
water transport in isolated cortical collecting tubules 
and toad bladder [9, lo]. Furthermore, in vivo studies in 
rat showed that renal arterial administration of 
5,6-EET-Me induces vasoconstriction concomitant 
with a reduction in glomerular filtration rate [6]. 
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Whereas biochemical studies of the epoxygenase 
reaction have been indispensable in the enzymatic 
characterization of this metabolic pathway, they pro- 
vide only limited information regarding its participa- 
tion in the metabolism of endogenous arachidonic acid, 
the in vivo formation of its metabolites and their organ 
steady state concentrations. We document herein the 
presence of EETs in human kidney and demonstrate 
the enantioselective formation of 14,15- and 11,12-EET 
by the human kidney cortex. 
2. MATERIALS AND METHODS 
Samples of human kidney cortex from adult males were obtained 
within 12 h of accidental death and maintained in liquid N2 until use. 
Prior to freezing, they were maintained in iced Euro-Collins solution 
as part of our routine protocol of maintaining tissue for human 
transplantation. Only organs excluded for human use for technical 
reasons were studied. The protocol utilized for EET extraction and 
purification is that of [I 11. Briefly, the frozen tissue was homogeniz- 
ed in CHsOH/HzO (2: 3 v/v; 20 ml/g wet tissue) containing 0.1 mM 
triphenylphosphine. Aliquots of the homogenates were transferred to 
test tubes containing an equivalent volume of a 2.0 mM solution of 
triphenylphosphine in CHCls and an equimolar mixture of 
[l-‘4C]EET internal standards (55 mCi/mmol) (0.02-0.03 pCi, 
0.15-0.13 pg, each of 14,15-, 11,12-and 8,9-EET). After mixing and 
centrifugation, the organic phase was collected and evaporated under 
argon. To the residue, 1 .O ml of 0.2 N KOH/CH3OH (2: 8 v/v) was 
added. After 1 h at 5O”C, the suspension pH was adjusted to 4.0, the 
organic material extracted into ethyl ether, concentrated under 
argon, dissolved in HOAc/hexane (0.5:99.5 v/v) and purified by 
SiOr column (200-400 mesh, 5 x 25 mm) as described [ll]. The 
radiolabeled EETs were resolved into 14,15-EET and a coeluting mix- 
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ture of 8,9- and 11,12-EET by reversed phase HPLC [ 111. The methyl 
ester of 14,15-EET was prepared as in [ll]. The mixture of 8,9- and 
11,12-EET was converted to the corresponding pentafluorobenzyl 
esters by reaction with pentafluorobenzyl bromide [ 111. The mixture 
of 8,9- and 11,12-EET-PFB was resolved by normal phase HPLC on 
a 5-pm Dynamax Microsorb Si column (4.6 x 250 mm, Rainin In- 
struments Co.) utilizing a solvent mixture of 2-propanol/hexane 
(0.17: 99.83 v/v), isocratically at 2 ml/min (&: 13.7 and 16.5 min for 
8,9- and 11,12-EET-PFB, respectively). The optical isomers of 
14,15-EET-Me, 8,9- and 11,12-EET-PFB were resolved utilizing 
either a Chiralcel OB (14,15_EET-Me) or a Chiralcel OD column (8,9- 
and 11,12-EET-PFB) (4.6 x 250 mm, J.T. Baker Chemical Co.) as 
described [12]. Absolute configurations were assigned as reported 
[ 121. The purified 8,9- and 11,12-EET-PFB enantiomers were analyz- 
ed and quantified by GC/NICI/MS. The resolved 14,15-EET-Me 
enantiomers were converted to their corresponding PFB ester 
derivatives as in [ 111. 
Aliquots of the purified EET-PFB enantiomers were dissolved in 
dodecane and analyzed by GC/NICI/MS on a Nermag RlOlOC 
quadrupole instrument utilizing a 30 m SPB-30 fused silica column 
(0.32 mm inner diameter, 0.25pm coating thickness, Supelco Inc., 
Bellefonte, PA) [ll]. Quantifications were done by 
GC/NICI/selected ion monitoring at m/z 319 (loss of PFB from the 
endogenous EET-PFB) and 321 (loss of PFB from the [l-‘4C]EET- 
PFB internal standard). The EET-PFB/[l-‘4C]EET-PFB sample 
ratios were calculated from the integrated values of the correspon- 
ding ion current intensities. The [l-‘4C]EET-PFB standards 
(55 mCi/mmol) were analyzed by GC/NICI/MS. All three standards 
showed an approximately 89 atom% enrichment in i4C, with the ex- 
pected base peak at m/z 321 (M-PFB). Enantiomerically pure 8,9-, 
11,12- and 14,15-EET were prepared by total asymmetric synthesis 
according to published procedures [13,14]. Racemic standards were 
prepared as in [15,16]. [I-“%]EET standards were synthesized from 
[I-“‘Clarachidonic acid (55 mCi/mmol, Amersham Co., Arlington 
Heights, IL) as described [I 11. 
3. RESULTS AND DISCUSSION 
Synthetic [I-r4C]EETs (55 mCi/mmol) were utilized 
as internal standards for the following reasons: (i) they 
are readily synthesized from [ 1 -14C]arachidonic acid 
available in high isotopic purity, (ii) they coelute with 
the corresponding endogenous [r2C20]EETs during all 
chromatographic procedures utilized, including chiral 
phase HPLC [ 111, (iii) they are easily quantified by li- 
quid scintillation techniques, and (iv) the molecular 
mass difference (2 amu) between the [l-‘4C]-labeled 
standards and the endogenous [12Czo]EETs permits 
quantification by NICI/GC/MS. The validity of this 
experimental approach has been demonstrated [111. 
Arachidonic acid autooxidation leads to the forma- 
tion of reactive hydroperoxides which can then serve as 
precursors for the artifactual recovery of several 
icosanoids [17,18]. To minimize artifactual EET 
generation during sample extraction and purification, 
the peroxide reducing agent triphenylphosphine was us- 
ed in all purification steps, prior to the removal of en- 
dogenous arachidonic acid by reversed phase HPLC. 
Control experiments demonstrated that under these ex- 
perimental conditions, autooxidation leading to EET is 
negligible and below our detection sensitivity [l 11. 
Since the labile 5,6-EET suffers extensive decomposi- 
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Fig. 1. Mass spectral fragmentation properties of the 12,12-EET- 
PFB enantiomers isolated from human kidney cortex. The 
1 l(R),12(S)- (top) and 1 l(S),lZ(R)-EET-PFB enantiomers (bottom) 
purified from human kidney cortex were dissolved in a small volume 
of dodecane and analyzed by NICI/GC/MS as described in section 
2. Shown are the fragmentation patterns generated by samples 
containing approximately 2 ng of each enantiomer. Abscissa, 
abundance as % of the base peak; ordinate, m/z. 
tion during the extraction and purification procedures 
utilized it was not further investigated. 
The overall recovery of the [l-14C]EET internal stan- 
dards, prior to GC/MS analysis, was 20070, 22070, and 
15% for 8,9-, 11,12- and 14,15-EET, respectively. 
Before quantification, each biological EET-PFB enan- 
tiomer was characterized by full scan NICI/GC/MS. 
For example, the material present in the biological 
samples with chromatographic properties identical to 
synthetic 1 l(R), 12(S)-EET-PFB showed ion fragments 
derived from the [l-14C]-labeled internal standard at 
m/z: 321 (9OVo abundance, loss of PFB) and 305 (4% 
abundance, loss of PFB and 0) (Fig. 2A). Diagnostic 
ions for the endogenous 1 l(R),lZ(S)-EET-PFB were at 
m/z: 319 (base peak, loss of PFB) and 301 (3% abun- 
dance, loss of PFB and HzO). The ion fragment at m/z 
303 (7% abundance) was common to both the internal 
standard (loss of Hz0 and PFB) and the endogenous 
EET (loss of 0 and PFB) (Fig. 2A). The fragment ions 
at m/z 322 and 320 (19% and 23% abundance, respec- 
tively) originate from the contribution of isotopic “C 
(1.108 atom% natural abundance) present in the en- 
dogenous and in the synthetic EET, after the loss of 
PFB (Fig. 2A). The mass spectra of the other enan- 
tiomer of 11,12-EET-PFB is shown in Fig. 2B. The 
fragmentation pattern of this sample shows the 
predominance of fragment ions derived from the 
[ 1 -r4C] 11 (S), 12(R)-EET-PFB internal standard at m/z 
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Fig. 2. Selected ion current profiles under NICI conditions for the 11,12=EET=PFB enantiomers present in human kidney cortex. The purified 
1 l(R),12(S)= (top) and 1 l(S),lZ(R)=EET=PFB were individually analyzed by NlCI/GC/selected ion monitoring at m/z 321 and 319 as described 
in section 2. The samples t4C/i2C ratios were calculated from the integrated areas under the observed peaks. Abscissa, retention time in minutes; 
ordinate, abundance relative to the most intense peak. 
Table I 
Regioisomeric omposition of the EETs isolated from human kidney 
cortex 
Table II 
Stereochemical properties of the human kidney cortex endogenous 
EETs 
EEG-regioisomer rig/g wet tissue % Distribution 
8,9=EET 75 f 14 23 
11,12=EET 110* 4 33 
14,15=EET 148 f 12 44 
The regioisomers of 8,9-, 11,12- and 14,15=EET were extracted, 
purified and quantified by NICI/GC/MS as described in section 2. 
Values are the averages f SE calculated from 5 different experiments 
performed with samples extracted from two different human 
kidneys. 
EET-regioisomer % R,S % S,R 
8,9=EET 51 zt 1 49 f 1 
11,12-EET 80 f 1 20 f 1 
14,15EET 66 f 1 34 f 1 
The enantiomers of 8,9=, 11,12= and 14,15=EET were purified, 
resolved and quantified as described in section 2. Values are the 
averages f SE calculated from 5 different experiments performed 
with samples extracted from two different human kidneys. 
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(070 abundance) 321 (lOO), 322 (22), 305 (4) and 303 (4). 
Fragment ions for the corresponding 12C20 endogenous 
enantiomer were at m/z (070 abundance) 319 (28), 320 
(S), 301 (2) (Fig. 2B). 
For quantification, aliquots of the purified biological 
samples were analyzed by GC/NICI/selected ion 
monitoring at 321 and 319. For each sample, the 
[ 1 -14C]EET-PFB standard/endogenous EET-PFB ratio 
was calculated by integration of the areas under the 
corresponding ion current profiles (Fig. 2 for 
11,12-EET-PFB). The concentration of each EET 
enantiomer in human kidney followed directly from the 
calculated ratio and the amount of internal standard 
added to the initial kidney homogenate. 
The tissue extracts contained 14,15-EET as their ma- 
jor component (44% of the total) followed by 11,12- 
and 8,9-EET (33% and 23070, respectively) (Table I). 
Quantitative analysis showed that human kidney cortex 
contains approximately 333 ng of total EET/g of wet 
tissue (Table I). This value is within the same order of 
magnitude as reported for rat and rabbit kidney 15,6]. 
Chiral analysis of the endogenous EETs in human 
kidney showed that 11,12- and 14,15-EET are produced 
enantioselectively whereas the 8,9-regioisomer is 
racemic (Table II). Since stereoselective formation of 
eicosanoids is a sufficient criterion to establish their en- 
zymatic origin we conclude that 11,12- and 14,15-EET 
are produced, in vivo, by the human kidney epoxy- 
genase. Although the evidence for the 8,9-regioisomer 
at present is not conclusive we propose the enzymatic 
formation of both 8,9-EET antipodes by individual 
cytochrome P-450 forms with opposing enantiofacial 
selectivities. We have previously demonstrated that the 
enantiofacial selectivity of the epoxygenase reaction is 
under regulatory control and is dependent on the tissue 
cytochrome P-450 isoenzyme composition [ 11,191. Ad- 
ditionally, the coexistence in the microsomal membrane 
of cytochrome P-450 epoxygenase forms with opposing 
enantioselectivities has been demonstrated [ 191. 
The key role of the cytochrome P-450 protein 
catalyst in controlling the stereoselectivity of oxygena- 
tion is further evidenced by comparing the data in 
Table II with published values for rat liver EETs [ 111. 
Thus, while the human renal and the rat liver epoxy- 
genase(s) showed similar stereoselectivity towards the 
arachidonate 14,15-olefin, they epoxidized the 
11,12-olefin with opposite enantiofacial selectivity, 
with the hepatic enzyme generating 1 l(S), 12(R)-EET as 
the major antipode [I 11. 
From the foregoing evidence, as well as published 
data [l 1,191, we conclude that the EETs are en- 
dogenous constituents of human kidney cortex 
generated, in vivo, by the tissue arachidonic acid 
epoxygenase. These results, in conjunction with the po- 
tent biological activities of the EETs, suggest a function 
for human renal cytochrome P-450(s) in the control of 
kidney function. 
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